GammaTile Brain Implant Reduces Tumor Recurrence in Phase III Trial

Study Findings and Clinical Efficacy

The ROADS trial was a randomized, multicenter study involving 230 patients across 32 medical centers. Investigators compared the performance of tile-based radiation therapy (TBRT) to standard postoperative stereotactic radiation therapy (SRT). According to the results, patients treated with the GammaTile implant experienced a significant reduction in tumor recurrence.

Data from the trial showed that the 12-month surgical bed recurrence rate dropped from 11.9% in the standard SRT group to 1.0% in the GammaTile cohort. Furthermore, the trial reported that median overall survival more than doubled for those receiving the implant compared to those receiving traditional postoperative radiation. Researchers observed a hazard ratio of 0.48, indicating a greater than 50% reduction in the risk of surgical bed recurrence or death. Notably, these improvements in efficacy were achieved without an increase in radiation toxicity or surgical complication rates.

How the Technology Works

GammaTile is an FDA-cleared, biodegradable collagen square roughly the size of a postage stamp. These tiles are embedded with titanium-encapsulated cesium-131 brachytherapy seeds. When implanted into the surgical cavity, the device provides continuous, localized radiation to the tissue surrounding the area where a tumor was removed.

The radiation delivery is designed to be immediate. While traditional radiation is typically administered four to six weeks after surgery, the GammaTile system allows surgeons to place the radiation source before closing the incision. The seeds deliver approximately 90% of their radiation dose within the first 33 to 35 days, with the tiles eventually absorbing into the body. The seeds themselves decay to become nonradioactive after 100 days.

Advantages Over Traditional Treatment

The transition to intraoperative radiation therapy addresses a significant “gap in care” noted by clinicians. Traditionally, the weeks-long wait between surgery and radiation can lead to complications. According to study investigators, approximately 20% to 30% of patients face difficulties returning for follow-up radiation due to health concerns, family issues, or logistical barriers such as transportation.

By integrating surgery and radiation into a single procedure, GammaTile allows patients to complete definitive local therapy in a median of one day, compared to approximately 30 days for those receiving postoperative SRT. This approach ensures that microscopic residual disease is treated immediately, preventing postoperative tumor repopulation. Additionally, the technology allows for the treatment of patients for whom another round of external beam radiation would be considered too toxic, such as those with recurrent gliomas or recurrent metastasis.

Practical Implications for Patients

The clinical impact of the GammaTile technology extends beyond convenience. By simplifying the treatment pathway, the implant may reduce delays in initiating systemic cancer therapies.

In clinical practice, the implant is currently being used for patients with newly diagnosed surgical brain metastases as well as those experiencing recurrence. For example, at Oregon Health & Science University (OHSU), the technology has been utilized to target tumors in critical areas, such as the portion of the brain controlling dominant hand function. OHSU physicians noted that the implant provides a valuable option for the 5% to 15% of patients whose cancer recurs after initial surgical and radiation treatment.

As the medical community reviews these findings, experts suggest the results represent a potentially groundbreaking advancement in neuro-oncology, shifting the focus toward optimizing local treatment pathways to better support long-term survival.